The antiviral future holds great promise for people living with HIV: better-tolerated, less toxic, drugs are about to come to market, and we are about to see the introduction of drugs from 1 or 2 new classes.
No CROI would be complete without presentations of antiretroviral drugs in the pipeline. The 2015 CROI was no different, even if there were relatively few presentations on clinical trials comparing various drugs and combinations. Given the success of currently available combinations, most of the pharmaceutical industry effort in this area has gone into co-formulating existing drugs into single-tablet, fixed-dose products. Nevertheless, there are a few drugs in the pipeline. Here are the highlights:
The future looks promising, as better-tolerated, less toxic drugs are about to come to market, and as we are about to see (within the next 2 years), the introduction of drugs from 1 or 2 new classes. Finally, it may be worth recalling that the first FDA-approved antiretroviral drug, zidovudine, became available in the US 28 years ago, in March 1987. We really have come a long way in less than one generation.
IDWeek 2023: New Data Provide Closer Look at Real-World Utilization of Cabotegravir for HIV PrEP
October 15th 2023IDWeek 2023. New study found just slightly more than half of prescriptions for cabotegravir for HIV PrEP resulted in at least 1 injection, suggesting limitations in use and access to the injectable HIV integrase inhibitor.
Common Side Effects of Antiretroviral Therapy in HIV Infection
February 7th 2013What are some of the more common side effects of antiretroviral therapy, and what can the primary care physician do to help manage these effects? In this podcast, infectious disease expert Rodger MacArthur, MD, offers insights and points readers to updated comprehensive guidelines.
IDWeek 2023: New Data Provide Closer Look at Real-World Utilization of Cabotegravir for HIV PrEP
October 15th 2023IDWeek 2023. New study found just slightly more than half of prescriptions for cabotegravir for HIV PrEP resulted in at least 1 injection, suggesting limitations in use and access to the injectable HIV integrase inhibitor.
Common Side Effects of Antiretroviral Therapy in HIV Infection
February 7th 2013What are some of the more common side effects of antiretroviral therapy, and what can the primary care physician do to help manage these effects? In this podcast, infectious disease expert Rodger MacArthur, MD, offers insights and points readers to updated comprehensive guidelines.
2 Commerce Drive
Cranbury, NJ 08512